Navigation Links
Asia-Pacific Seasonal Influenza Vaccine Market to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity : MarketResearchReports.biz
Date:4/6/2013

Albany, New York (PRWEB) April 07, 2013

Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity, High Investment and Strict Regulations as Barriers to New Entrants which essentially provides insights into the seasonal influenza vaccine sales forecasts for the Asia-Pacific Region until 2018. The report also delves deep into vaccination patterns for seasonal influenza in the Asia-Pacific Region. Further, the geographical distribution of seasonal influenza vaccines across Japan, Australia, New Zealand, China, Taiwan, Philippines, Hong Kong, Malaysia, India and Singapore are also provided in the report.

To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis-details/seasonal-influenza-vaccine-market-in-asia-pacific-to-2018-positive-impact-of-government-support-offset-by-limited-production-capacity-high-investment-and-strict-regulations-as-barriers-to-new-entrants

The report offers a clear view of the regulatory landscape in the Asia-Pacific countries. The report also reveals the seasonal influenza vaccine R&D pipeline and offers profiles of promising vaccines. The report explores the competitive landscape including profiles for top companies. Finally, the key trend analysis on mergers and acquisitions, and licensing agreements involving seasonal influenza vaccines is also presented. Treatment of seasonal influenza is dominated by two categories of treatment options, vaccines and antiviral therapies. In the recent years it was observed that demand for seasonal influenza vaccines have increased due to changed perception of patient population.

The patient population is of the opinion that preventive healthcare is better compared to curative healthcare; this led to increased demand of vaccines in Asia-Pacific region. Asia-Pacific (APAC) region is an attractive market for seasonal influenza vaccine manufacturers. Major drivers in the market is increasing awareness, increasing vaccination coverage in the APAC countries and rising government support for immunization against seasonal influenza. Major restraints of the market are variable demand and limited production capacity. Traditional egg based manufacturing of seasonal influenza vaccines is being replaced with cell culture vaccines. Cell culture based production of vaccines is expected to reduce the problems associated with the production and use of seasonal influenza vaccines which will further increase the vaccination coverage in the APAC region.

Latest Report: Solution Styrene Butadiene Rubber (S-SBR) Market For Tire, Polymer Modification, Footwear & Others - Global Industry Analysis, Size, Share, Growth And Forecast, 2012 - 2018

GBI Research Analysis shows that the seasonal influenza vaccine market in the APAC Region is a fast growing market. This is due to increased vaccination coverage against seasonal influenza in the region. GBI Research forecasts the market to grow at double digit Compounded Annual Growth Rate (CAGR) of 9% during the period 2011–2018 from $1,015m in 2011 to $1,879m by 2018. This growth is driven by factors such as increasing awareness on influenza caused by threat of pandemic influenza, increasing vaccination coverage because of the governments’ support, growing population in the APAC region and entry of novel vaccines and production technologies. GBI Research finds that the Philippines’ seasonal influenza vaccine market is the most attractive in the seasonal influenza vaccine market for Asia-Pacific region both in terms of value and growth rate.

Other attractive markets in terms of growth rate are Malaysia’s and Singapore’s seasonal influenza vaccine markets. Australia’s seasonal influenza vaccine market is also a large sized attractive market forecast to grow at a healthy growth rate during the period 2011–2018. In-depth analysis of the report is based on propriety databases, primary and secondary research and in house analysis by the GBI Research team of experts. GBI Research analysis shows that the R&D pipeline for the seasonal influenza vaccines is moderately strong with approximately 50% of the pipeline in the Phase II and Phase III. The major vaccine manufacturers are focused upon acquiring new technologies and strengthening their presence in the market by collaborating with or acquiring small and medium sized biotech companies that have strong vaccine candidates in their pipeline. The R&D activity also indicates development of new technologies and novel vaccines that can revolutionize the market in near future.

Related Report:Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players

Scope

The report analyses vaccination patterns, market characterization, regulatory landscape, pipeline analysis, competitive landscape and key M&A trends in the seasonal influenza vaccine market in the APAC region.

The report covers:
Data and analysis on the seasonal influenza vaccine market in the Asia-Pacific Region including Japan, Australia, New Zealand, China, Taiwan, Philippines, Malaysia, Hong Kong, India and Singapore.
Market forecasts for the seasonal influenza vaccines from 2011 to 2018
Market Data on geographical landscape including country wise vaccination coverage, public and private contribution on total doses, price of vaccine, market size and market share.
Key drivers and restraints that have created significant impact on the market.
Regulatory landscape including the pharmaceutical product approval process and overview of regulatory authorities in the countries in Asia-Pacific region
Competitive landscape of the seasonal influenza vaccine market in Asia-Pacific region including top companies profiles. The key companies studied in this report are Sanofi Pasteur, Abbott Laboratories, GlaxoSmithKline Biologicals, Novartis Vaccines, CSL Biotherapies and Crucell.
Key M&A activities, Licensing Agreements, that have taken place between 2007 and 2012 in the seasonal influenza vaccine market.

Reasons to Buy

The report will aid business development and marketing executives strategizing their product launches:

    Build effective strategies to launch their pipeline products by identifying potential geographies.
    Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.
    Develop key strategic initiatives by studying the key strategies of top competitors.
    Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
    Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class vaccines with more efficacy and better safety.

For All Market Research Reports visit: http://www.marketresearchreports.biz/

Read the full story at http://www.prweb.com/releases/2013/marketresearchreports/prweb10604422.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Does Your Child Have Seasonal Allergies or a Cold?
2. NYC Doc Announces 3 Surprising Ways to Beat Seasonal Allergies
3. Study examines role of seasonal prescribing changes in antibiotic resistance
4. A Delicious, And Healthy New Seasonal Hot Chocolate Beverage, Xocai's Sipping Xocolate, Has Been Released By Marketing Xocolate International Corporation (MXI Corp)
5. Strains of antibiotic-resistant Staph bacteria show seasonal preference; Children at higher risk in summer
6. Prediction of seasonal flu strains improves chances of universal vaccine
7. Measuring the uncertainties of pandemic influenza
8. New influenza virus from seals highlights the risks of pandemic flu from animals
9. Reconstructed 1918 influenza virus has yielded key insights, scientists say
10. Influenza vaccine may reduce risk of heart disease and death
11. Patients can emit small, influenza-containing particles into the air during routine care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... America . ... ... ... ...
Breaking Medicine Technology: